尖峰集团：关于子公司获得药物临床试验批准通知书的公告

Core Viewpoint - The company announced that its subsidiary has received approval for a new drug clinical trial from the National Medical Products Administration [1] Group 1 - The full subsidiary involved is Zhejiang Jianfeng Pharmaceutical Co., Ltd. [1] - The holding subsidiary that received the approval is Zhejiang Jianfeng Yien Biotechnology Co., Ltd. [1] - The approved drug is named JFAN-1001 mesylate capsule [1] Group 2 - The approval includes three notification numbers: 2025LP03024, 2025LP03025, and 2025LP03026 [1]